de Bruyn Magali, Vandooren Jennifer, Ugarte-Berzal Estefania, Arijs Ingrid, Vermeire Séverine, Opdenakker Ghislain
a Laboratory of Immunobiology, Department of Microbiology and Immunology, KU Leuven , Rega Institute for Medical Research , Leuven , Belgium.
b Department of Clinical and Experimental Medicine, KU Leuven , Translational Research Center for Gastrointestinal Disorders (TARGID) , Leuven , Belgium.
Crit Rev Biochem Mol Biol. 2016 Sep;51(5):295-358. doi: 10.1080/10409238.2016.1199535. Epub 2016 Jun 30.
Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are thought to be predominant proteases and protease inhibitors involved in the pathogenesis of inflammatory bowel diseases (IBD) through their ability to remodel the extracellular matrix (ECM) in response to inflammatory stimuli and by their immunomodulating effects. An imbalance between MMPs and TIMPs has been linked with acute and chronic inflammation and aberrant tissue remodeling, as seen in IBD. Moreover, recurrent phases of tissue destruction and subsequent tissue repair can cause serious complications in IBD patients such as fistulas and fibrosis. The aims of this review are (i) to summarize current literature on genetic association, mRNA, and protein expression studies with regard to MMPs and TIMPs in IBD patients and various animal models, including those with transgenic and knockout mice; (ii) to compare biochemical and molecular biological data in humans with those obtained in animal model studies and (iii) to critically evaluate and translate how this knowledge may be used in practical terms to understand better the pathophysiology and mechanisms operating in IBD and to apply this for improvement of clinical outcomes at diagnostic, prognostic and therapeutic levels.
基质金属蛋白酶(MMPs)和金属蛋白酶组织抑制剂(TIMPs)被认为是主要的蛋白酶和蛋白酶抑制剂,它们通过响应炎症刺激重塑细胞外基质(ECM)的能力以及免疫调节作用,参与炎症性肠病(IBD)的发病机制。如在IBD中所见,MMPs和TIMPs之间的失衡与急性和慢性炎症以及异常的组织重塑有关。此外,组织破坏的反复阶段和随后的组织修复可导致IBD患者出现严重并发症,如瘘管和纤维化。本综述的目的是:(i)总结关于IBD患者和各种动物模型(包括转基因和基因敲除小鼠)中MMPs和TIMPs的遗传关联、mRNA和蛋白质表达研究的当前文献;(ii)将人类的生化和分子生物学数据与动物模型研究中获得的数据进行比较;(iii)批判性地评估并转化这些知识如何实际用于更好地理解IBD的病理生理学和作用机制,并将其应用于改善诊断、预后和治疗水平的临床结果。